Document › Details

UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels.

	Organisation	UCB S.A. (Euronext: UCB)
	Group	UCB (Group)
	Product	Cimzia®
	Product 2	Vimpat®
	Person	Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
	Person 2	Witte, Antje (UCB 201601 Investor Relations)

Original document
accessed by [iito] on 2019-03-01

Record changed: 2019-03-06

More documents for UCB (Group)

[1] UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels....
[2] UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels....
[3] UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough....
[4] UCB S.A.. (2/11/19). "Press Release: UCB and Epilepsy Society Announce Pioneering UK Genomics R&D collaboration". Slough & Brussels....
[5] UCB S.A.. (7/13/18). "Press Release: UCB and Amgen Resubmit Biologics Licence Application (BLA) for Evenity (Romosozumab) to the U.S. FDA". Brussels & Thousand Oaks, CA....
[6] StrideBio, Inc.. (6/13/18). "Press Release: StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform". Durham, NC....
[7] Science 37 Inc.. (5/3/18). "Press Release: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home". Playa Vista, CA....
[8] UCB S.A.. (4/27/18). "Press Release: UCB Announces Positive CHMP Opinion for Cimzia (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis". Brussels....
[9] UCB S.A.. (4/25/18). "Press Release: UCB First Three Months Interim Report 2018. UCB Tracking Well towards Full Year Financial Outlook". Brussels....
[10] UCB S.A.. (4/20/18). "Press Release: UCB to Expand Epilepsy Portfolio with Strategic Acquisition of Midazolam Nasal Spray from Proximagen". Brussels....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]